Summary by Moomoo AI
WuXi Biologics (Cayman) Inc. submitted its latest monthly report on securities changes to the Hong Kong Exchanges and Clearing Limited on September 2, 2024, reporting the share changes as of August 31, 2024. The report shows that the company's statutory/registered capital remains unchanged at 6,000,000,000 shares, with a par value of USD1/120,000, and a total statutory/registered capital of $50,000. As for the issued shares, the end-of-month balance is 4,153,329,356 shares, an increase of 46,957 shares compared to the previous month. This increase is mainly due to the exercise of stock options, including the pre-emptive stock option plan, with a total amount of $9,197.06 raised from exercising the options this month. In addition, the company repurchased and intends to cancel 1,810,000 ordinary shares on June 11, 2024, which have not been cancelled as of the report's end date. The report also confirms that all securities issuances or sales of treasury shares have been formally authorized by the board of directors and comply with all applicable listing rules, laws, and other regulatory requirements.
